Profil
Dr. Peter Traxler is Vice President-Drug Development at Oncalis AG.
Dr. Traxler was previously employed as a Principal by Novartis Pharma Schweiz AG.
Anciens postes connus de Peter Traxler
| Sociétés | Poste | Fin |
|---|---|---|
Oncalis AG
 Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Corporate Officer/Principal | 14/12/2011 |
Novartis Pharma Schweiz AG
 Novartis Pharma Schweiz AG Miscellaneous Commercial ServicesCommercial Services Novartis Pharma Schweiz AG engages in the marketing and distribution of pharmaceutical, chemical, and medical products of the Novartis group. Its products are used in the treatment of diseases in the areas of neurology, immunology, dermatology, ophthalmology, cardiology, and oncology. The company was founded on December 10, 1986 and is headquartered in Rotkreuz, Switzerland. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Oncalis AG
Oncalis AG Pharmaceuticals: MajorHealth Technology Oncalis AG ('Oncology alliances') has been founded in June 2006 as a spin-off from ESBATech AG, a Swiss biotechnology company that has developed technology platforms in both the antibody and small molecule areas of pharmaceutical research. Oncalis has acquired from the mother company all small molecule-related assets, including a yeast-cell based, high- throughput screening platform for receptor tyrosine kinases (RTKs), and a number of specific and potent kinase inhibitors. The company is currently financed by ESBATech's Series A investors, including Novartis Venture Fund, BioMedInvest and Venture Incubator (VI) Partners. Oncalis will now focus on the discovery and development of small molecule inhibitors for oncology indications. | Health Technology |
Novartis Pharma Schweiz AG
Novartis Pharma Schweiz AG Miscellaneous Commercial ServicesCommercial Services Novartis Pharma Schweiz AG engages in the marketing and distribution of pharmaceutical, chemical, and medical products of the Novartis group. Its products are used in the treatment of diseases in the areas of neurology, immunology, dermatology, ophthalmology, cardiology, and oncology. The company was founded on December 10, 1986 and is headquartered in Rotkreuz, Switzerland. | Commercial Services |
